Regenerative Medical Technology Group annual ebitda
2023
2024
2025
Regenerative Medical Technology Group EBITDA Growth & History (RMTG)
Regenerative Medical Technology Group's calculated EBITDA was −$586,095 for fiscal 2025.
View full Regenerative Medical Technology Group company overviewRegenerative Medical Technology Group annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$586,095 | −$887,835 | — |
| 2024 | 2024-12-31 | $301,740 | $706,864 | — |
| 2023 | 2023-12-31 | −$405,124 | — | — |
Regenerative Medical Technology Group quarterly ebitda
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $656,787 | $852,042 | — |
| Q1 2026 | 2026-03-31 | $327,477 | $140,703 | +75.33% |
| Q4 2025 | 2025-12-31 | −$207,931 | −$560,738 | — |
| Q3 2025 | 2025-09-30 | −$369,683 | −$478,159 | — |
| Q2 2025 | 2025-06-30 | −$195,255 | −$64,245 | — |
| Q1 2025 | 2025-03-31 | $186,774 | $215,307 | — |
| Q4 2024 | 2024-12-31 | $352,807 | — | — |
| Q3 2024 | 2024-09-30 | $108,476 | — | — |
| Q2 2024 | 2024-06-30 | −$131,010 | — | — |
| Q1 2024 | 2024-03-31 | −$28,533 | — | — |
Regenerative Medical Technology Group ebitda trends
Across the available reported history, Regenerative Medical Technology Group's ebitda decreased from $301,740 to −$586,095, a change of −$887,835. The latest reported quarter, Q2 2026, shows $656,787.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regenerative Medical Technology Group filings at SEC.gov ↗